Lloyd Mabonga1, Paul Chukwudi Ikwegbue2, Priscilla Masamba3, Abidemi Paul Kappo3. 1. Department of Biochemistry and Microbiology, University of Zululand KwaDlangezwa 3886, South Africa. 2. Division of Immunology, Department of Pathology, Faculty of Health Sciences, University of Cape Town Cape Town, South Africa. 3. Molecular Biophysics and Structural Biology (MBSB) Group, Department of Biochemistry, Faculty of Science, University of Johannesburg, Auckland Park Kingsway Campus South Africa.
Abstract
BACKGROUND: Targeting protein-protein interactions (PPIs) linked to protein quality control (PQC) pathways as potential anti-cancer drug targets have unanimously widened biological insights and the therapeutic potential of PPIs as smart-drug discovery tools in cancer. PPIs between disease-relevant proteins associated with protein homeostasis in PQC pathways have been linked to improved mechanistic understanding associated with conformational abnormalities and impairment, cellular proteotoxicity, induced apoptosis, and pathogenesis in different types of cancers. In this context, PPIs between small nuclear ribonucleoprotein polypeptide G (SNRPG) and heat shock protein 70.14 (Hsp70.14) have attracted attention as potential smart drug discovery tools in cancer diagnostics and therapeutics. Validated evidence of high-quality biological data has shown the presence of the two proteins in different types of cancers including breast cancer. The links between SNRPG and Hsp70.14 in cancer-cell networks remain elusive, overlooked, and uncharacterized. METHODOLOGY: In this study, we explored the interaction between the two oncogenic proteins using the MST-based assays. RESULTS: The results revealed a low KD in the nanomolar concentration range of 2.4673 × 10-7 demonstrating a great affinity for SNRPG binding to Hsp70.14. CONCLUSIONS: The results suggest a possible involvement between the two proteins in hostile tumour microenvironments. Furthermore, these findings offer a different therapeutic perspective that could pave the way for the creation of novel small molecule inhibitors as drugs for the treatment of cancer. AJTR
BACKGROUND: Targeting protein-protein interactions (PPIs) linked to protein quality control (PQC) pathways as potential anti-cancer drug targets have unanimously widened biological insights and the therapeutic potential of PPIs as smart-drug discovery tools in cancer. PPIs between disease-relevant proteins associated with protein homeostasis in PQC pathways have been linked to improved mechanistic understanding associated with conformational abnormalities and impairment, cellular proteotoxicity, induced apoptosis, and pathogenesis in different types of cancers. In this context, PPIs between small nuclear ribonucleoprotein polypeptide G (SNRPG) and heat shock protein 70.14 (Hsp70.14) have attracted attention as potential smart drug discovery tools in cancer diagnostics and therapeutics. Validated evidence of high-quality biological data has shown the presence of the two proteins in different types of cancers including breast cancer. The links between SNRPG and Hsp70.14 in cancer-cell networks remain elusive, overlooked, and uncharacterized. METHODOLOGY: In this study, we explored the interaction between the two oncogenic proteins using the MST-based assays. RESULTS: The results revealed a low KD in the nanomolar concentration range of 2.4673 × 10-7 demonstrating a great affinity for SNRPG binding to Hsp70.14. CONCLUSIONS: The results suggest a possible involvement between the two proteins in hostile tumour microenvironments. Furthermore, these findings offer a different therapeutic perspective that could pave the way for the creation of novel small molecule inhibitors as drugs for the treatment of cancer. AJTR
Authors: Jeffrey M Axten; Jesús R Medina; Yanhong Feng; Arthur Shu; Stuart P Romeril; Seth W Grant; William Hoi Hong Li; Dirk A Heerding; Elisabeth Minthorn; Thomas Mencken; Charity Atkins; Qi Liu; Sridhar Rabindran; Rakesh Kumar; Xuan Hong; Aaron Goetz; Thomas Stanley; J David Taylor; Scott D Sigethy; Ginger H Tomberlin; Annie M Hassell; Kirsten M Kahler; Lisa M Shewchuk; Robert T Gampe Journal: J Med Chem Date: 2012-08-08 Impact factor: 7.446
Authors: Pengyu Huang; Ingrid Almeciga-Pinto; Matthew Jarpe; John H van Duzer; Ralph Mazitschek; Min Yang; Simon S Jones; Steven N Quayle Journal: Oncotarget Date: 2017-01-10
Authors: M Ri; E Tashiro; D Oikawa; S Shinjo; M Tokuda; Y Yokouchi; T Narita; A Masaki; A Ito; J Ding; S Kusumoto; T Ishida; H Komatsu; Y Shiotsu; R Ueda; T Iwawaki; M Imoto; S Iida Journal: Blood Cancer J Date: 2012-07-20 Impact factor: 11.037